Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EINSTEIN CYP: Rivaroxaban in DVT/PE with CYP3A4 Inducers
NCT00786422Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in deep vein thrombosis (DVT) and pulmonary embolism (PE), sponsored by Bayer. Primary endpoints: Prothrombin Time up to 3 months, Area Under the Curve at Steady State and 3 more. Started May 2009; status: completed.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT00786422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00786422.